Merck and Eisai Reveal Latest Data from P-III (LEAP-015) Trial of Keytruda (pembrolizumab) and Lenvima (lenvatinib) Regimen to Treat Gastroesophageal Adenocarcinoma
Shots:
- P-III (LEAP-015) trial assessed Keytruda + Lenvima + CT (CAPOX or mFOLFOX6 regimen) as a 1L therapy for LA/M inoperable HER2- GE adenocarcinoma pts in 2 parts (P1: safety run-in & P2: main trial). LEAP program is also assessing it in hepatocellular carcinoma & esophageal cancer
- P2 pts (n=880) received Keytruda (400mg, IV Q6W, 2 cycles) + Lenvima (8mg, QD) + CT for ~12wks., followed by Keytruda (≤16 doses) + Lenvima (20mg, QD) or CT in consolidation phase. 1EPs were OS & PFS assessed in PD-L1+ (CPS ≥1) pts & all pts; 2EPs were ORR & DOR assessed in all pts
- Interim analysis showed improved PFS & ORR, failed to meet OS at the final analysis. Ongoing full evaluation data will be presented at future meetings; these results will not affect other ongoing trials
Ref: Merck & Eisai | Image: Merck & Eisai
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
